Hemo Organic
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Dineshbhai Shanabhai Patel sold 155,986 equity shares of Hemo Organic in an off-market transaction on 24 October 2026. His shareholding fell from 164,968 shares representing 2.40% of voting capital to 8,982 shares representing 0.13%. The company's equity capital stood at 68,65,900 shares of Rs10 each. Sonalben Dineshbhai Patel was listed as a person acting in concert with the seller.
Powered by Tijori
Dineshbhai Shanabhai Patel sold 155,986 equity shares of Hemo Organic in an off-market transaction on 24 October 2026. His shareholding fell from 164,968 shares representing 2.40% of voting capital to 8,982 shares representing 0.13%. The company's equity capital stood at 68,65,900 shares of Rs10 each. Sonalben Dineshbhai Patel was listed as a person acting in concert with the seller.
Powered by Tijori
Hemo Organic's board on 3 October 2026 approved alteration of the main objects clause of its memorandum to cover trading in rough, polished, natural and laboratory-grown diamonds, diamond cutting, polishing, grading and processing, real estate development and investment in related businesses, subject to shareholder and regulatory approvals. The board also approved increasing authorised share capital to Rs125 crore divided into 12,50,00,000 shares of Rs10 each from Rs13.45 crore divided into 1,34,50,000 shares. It appointed Pratibha Sharma as company secretary and compliance officer with effect from 3 October and deferred the proposal for raising funds to a subsequent board meeting with no decision taken.
Powered by Tijori
Hemo Organic's board on 3 October 2026 approved alteration of the main objects clause of its memorandum to cover trading in rough, polished, natural and laboratory-grown diamonds, diamond cutting, polishing, grading and processing, real estate development and investment in related businesses, subject to shareholder and regulatory approvals. The board also approved increasing authorised share capital to Rs125 crore divided into 12,50,00,000 shares of Rs10 each from Rs13.45 crore divided into 1,34,50,000 shares. It appointed Pratibha Sharma as company secretary and compliance officer with effect from 3 October and deferred the proposal for raising funds to a subsequent board meeting with no decision taken.
Powered by Tijori
Hemo Organic's promoter-group shareholders Dineshbhai Shanabhai Patel and Sonalben Dineshbhai Patel entered share purchase agreements on 22 September 2026 to sell a combined 5,67,958 shares representing 16.38% of paid-up capital. The buyers were Ketanaben Jasani, Heema Makadia, V9BIZ Business Solution LLP and Jasani Family Trust, with the stake equating to 8.27% on a fully diluted basis assuming conversion of outstanding warrants. The company was not a party to the agreements, which envisaged off-market transfers with no special rights to appoint directors or restrict capital structure.
Powered by Tijori
Hemo Organic's promoter-group shareholders Dineshbhai Shanabhai Patel and Sonalben Dineshbhai Patel entered share purchase agreements on 22 September 2026 to sell a combined 5,67,958 shares representing 16.38% of paid-up capital. The buyers were Ketanaben Jasani, Heema Makadia, V9BIZ Business Solution LLP and Jasani Family Trust, with the stake equating to 8.27% on a fully diluted basis assuming conversion of outstanding warrants. The company was not a party to the agreements, which envisaged off-market transfers with no special rights to appoint directors or restrict capital structure.
Powered by Tijori
March 11 (Reuters) - Hemo Organic Ltd HEMO.BO:
HEMO ORGANIC LTD - AVINASHSINGH BIRENDRASINGH RAJPUT DID NOT PROVIDE THEIR CONSENT TO ACT AS CFO
Source text for Eikon: ID:nBSE8jHhFg
Further company coverage: HEMO.BO
(([email protected];))
March 11 (Reuters) - Hemo Organic Ltd HEMO.BO:
HEMO ORGANIC LTD - AVINASHSINGH BIRENDRASINGH RAJPUT DID NOT PROVIDE THEIR CONSENT TO ACT AS CFO
Source text for Eikon: ID:nBSE8jHhFg
Further company coverage: HEMO.BO
(([email protected];))
Nov 8 (Reuters) - Hemo Organic Ltd HEMO.BO:
APPOINTED AVINASHSINGH BIRENDRASINGH RAJPUT AS CHIEF FINANCIAL OFFICER
MRUGESH PATEL RESIGNS AS CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:nBSE2kTgRY
Further company coverage: HEMO.BO
(([email protected];))
Nov 8 (Reuters) - Hemo Organic Ltd HEMO.BO:
APPOINTED AVINASHSINGH BIRENDRASINGH RAJPUT AS CHIEF FINANCIAL OFFICER
MRUGESH PATEL RESIGNS AS CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:nBSE2kTgRY
Further company coverage: HEMO.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Hemo Organic do?
Dinesh Allorga Ltd specializes in the production and sale of ayurvedic medicines and chemicals.
Who are the competitors of Hemo Organic?
Hemo Organic major competitors are Desh Rakshak Aushdh, Shamrock Indl. Co, Norris Medicines, Beryl Drugs, Unjha Formulations, Saroja Pharma Inds., Emmessar Biotech&Nut. Market Cap of Hemo Organic is ₹14 Crs. While the median market cap of its peers are ₹14 Crs.
Is Hemo Organic financially stable compared to its competitors?
Hemo Organic seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Hemo Organic pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Hemo Organic latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Hemo Organic allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments, Capital Work in Progress, Short Term Loans & Advances
How strong is Hemo Organic balance sheet?
Balance sheet of Hemo Organic is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Hemo Organic improving?
The profit is oscillating. The profit of Hemo Organic is -₹0.73 Crs for TTM, -₹0.78 Crs for Mar 2026 and ₹0.16 Crs for Mar 2025.
Is the debt of Hemo Organic increasing or decreasing?
The net debt of Hemo Organic is decreasing. Latest net debt of Hemo Organic is ₹1.28 Crs as of Sep-26. This is less than Mar-26 when it was ₹2.72 Crs.
Is Hemo Organic stock expensive?
Hemo Organic is not expensive. Latest PE of Hemo Organic is 0, while 3 year average PE is 15.56. Also latest EV/EBITDA of Hemo Organic is 0.0 while 3yr average is 3.16.
Has the share price of Hemo Organic grown faster than its competition?
Hemo Organic has given better returns compared to its competitors. Hemo Organic has grown at ~53.72% over the last 3yrs while peers have grown at a median rate of 9.47%
Is the promoter bullish about Hemo Organic?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Hemo Organic is 2.51% and last quarter promoter holding is 16.85%. Please check if dilutions happened via QIP/ Offerings etc.
Are mutual funds buying/selling Hemo Organic?
There is Insufficient data to gauge this.